Michael Sinclair net worth and biography

Michael Sinclair Biography and Net Worth

Director of Opiant Pharmaceuticals

Dr. Sinclair has developed and managed healthcare companies for over forty years. He is Executive Chairman of Advanced Oncotherapy, PLC. He has served on the Board of Overseers (emeritus) of the Tufts University School of Medicine since 1993. In 1994 he founded U.S.-based Atlantic Medical Management LLP, which managed the New York based healthcare venture fund, Atlantic Medical Capital LP, where he served as Chairman until 2001. As Executive Chairman of Lifetime Corporation, which he founded, he was instrumental in growing its KQC subsidiary from one office in Nashville to a business with a turnover of $1 billion between 1982 and 1993. He acted as President (International) of INA Healthcare Group (subsequently CIGNA) and its Hospital Affiliates Inc. subsidiary between 1979 and 1982. His transition to business came when he founded and acted as Chief Executive of Nestor PLC in 1971. As a physician specializing in psychiatry, he began his medical career at Middlesex Hospital in London in 1967.

What is Michael Sinclair's net worth?: The estimated net worth of Michael Sinclair is at least $0.00 as of June 15th, 2022. Mr. Sinclair owns 19,220 shares of Opiant Pharmaceuticals stock worth more than $0 as of December 22nd. This net worth evaluation does not reflect any other investments that Mr. Sinclair may own. Learn More about Michael Sinclair's net worth.
How do I contact Michael Sinclair?: The corporate mailing address for Mr. Sinclair and other Opiant Pharmaceuticals executives is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. Opiant Pharmaceuticals can also be reached via phone at (310) 598-5410 and via email at [email protected]. Learn More on Michael Sinclair's contact information.
Has Michael Sinclair been buying or selling shares of Opiant Pharmaceuticals?: Michael Sinclair has not been actively trading shares of Opiant Pharmaceuticals during the last ninety days. Most recently, Michael Sinclair sold 900 shares of the business's stock in a transaction on Wednesday, June 15th. The shares were sold at an average price of $10.60, for a transaction totalling $9,540.00. Following the completion of the sale, the director now directly owns 19,220 shares of the company's stock, valued at $203,732. Learn More on Michael Sinclair's trading history.
Who are Opiant Pharmaceuticals' active insiders?: Opiant Pharmaceuticals' insider roster includes Craig Collard (Director), Roger Crystal (CEO), David O'Toole (CFO), Matthew Ruth (Insider), Michael Sinclair (Director), Phil Skolnick (Insider), and Thomas Thomas (Director). Learn More on Opiant Pharmaceuticals' active insiders.

Michael Sinclair Insider Trading History at Opiant Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/15/2022	Sell	900	$10.60	$9,540.00	19,220
6/6/2022	Sell	7,688	$12.94	$99,482.72	41,532
6/2/2022	Sell	9,736	$13.88	$135,135.68	59,484
8/25/2021	Sell	50,269	$14.69	$738,451.61
8/23/2021	Sell	65,124	$16.50	$1,074,546.00	209,194
9/12/2019	Sell	60,000	$12.52	$751,200.00
1/17/2017	Buy	3,500	$7.01	$24,535.00	132,720

Michael Sinclair Buying and Selling Activity at Opiant Pharmaceuticals

Opiant Pharmaceuticals Company Overview

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

Today's Range

Now: N/A

50 Day Range

MA: $20.58

$20.03

$21.10

2 Week Range

Now: N/A

Volume

562,700 shs

Average Volume

77,920 shs

Market Capitalization

$108.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Trump’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW